IDEAYA Biosciences GAAP EPS of -$1.22 misses by $0.03, revenue of $10.24M beats by $2.66M (IDYA:NASDAQ)
IDEAYA Biosciences reported Q3 GAAP EPS of -$1.22, missing estimates by $0.03, but revenue of $10.24M beat expectations by $2.66M. The company had $1.15B in cash and equivalents as of September 30, 2026, with its cash runway guidance into 2030 remaining unchanged.
How this was made
The 30-second read
Why it matters
The EPS miss may trigger short-term sell pressure, while the cash position supports longer-term stability.
Market read
Primary earnings disclosure for a micro-cap; modest trading relevance.
What to watch
Cash runway into 2030 remains strong, providing financial flexibility.
Background
IDEAYA Biosciences reported its Q3 earnings, a routine quarterly update for a biotech micro-cap.
Ticker impact
Q3 GAAP EPS of -$1.22 missed expectations by $0.03; revenue of $10.24M beat by $2.66M.
likely pressure as market prices in the EPS miss
The EPS miss is a primary earnings disclosure; investors typically react negatively to a miss, even with a revenue beat.
Market effects
Minimal impact on broader biotech sector; earnings miss may slightly dampen sentiment.
Limited to US-listed micro-cap investors.
Low
Counterpoint
Revenue beat could signal growth potential despite EPS miss.
Key entities
- CompanyIDEAYA Biosciences
Biotech firm listed on NASDAQ under ticker IDYA.
